DLA Piper announced today that Ellen Scordino, Susan Krumplitsch and April Abele Isaacson have joined the firm's Patent Litigation practice and Life Sciences sector. Scordino joins as a partner based in the Boston office, Krumplitsch joins as a partner in Silicon Valley and Isaacson joins as of counsel in San Francisco.
The group brings extensive experience representing pharmaceutical, biotechnology, chemical and medical device companies in patent litigation and other intellectual property matters.
Scordino focuses on patent litigation and client counseling in the pharmaceuticals, biologics, diagnostics, and medical device industries. She has particular experience with Hatch-Waxman and BPCIA litigations and has led trial teams in obtaining favorable judgments and settlements in district courts and inter partes review proceedings. Scordino has also worked extensively with clients to create patent and litigation strategies mindful of regulatory issues and the FDA. She works with large innovator pharmaceutical companies, established biotechnology companies and startups.
Krumplitsch handles intellectual property disputes and strategic counseling for life sciences companies, with an emphasis on Hatch-Waxman and BPCIA litigation. She represents innovative biotechnology, pharmaceutical and medical device companies in trial and appellate proceedings in federal courts across the country and in post grant review proceedings at the US Patent and Trademark Office.
Isaacson focuses on representing pharmaceutical companies in biologic and drug patent litigation, including Hatch-Waxman litigation. Over her career, Isaacson has tackled a wide range of intellectual property issues in the pharmaceutical, biotechnology, chemical and medical device industries, working from in-house and outside counsel positions. Prior to attending law school, Isaacson was an HIV/AIDS research scientist at Boston Children’s Hospital.
“Ellen, Susan and April bring an incredible combination of experience to the firm, including having served as lead trial counsel in Hatch-Waxman litigation and other life sciences patent litigation,” said Ann Ford, global co-chair and US chair of DLA Piper's Intellectual Property and Technology practice. "Their addition to our practice will enable us to better serve the needs of our life science clients across our global platform."
With the addition of Scordino, Krumplitsch and Isaacson, DLA Piper continues its focus and commitment on expanding its Life Sciences sector, which also recently welcomed life sciences veterans Michael Sitzman and Sam Deka in San Francisco.
"Susan and April will immediately expand our capabilities in Northern California, where demand for experienced and knowledgeable counsel has continued to increase rapidly in the pharmaceutical and biotechnology industries," said Victoria Lee, the firm’s managing partner for Northern California and global co-chair of the Technology sector. “We are thrilled to welcome this group to the firm.”
"In Boston, the market for technology and life sciences companies is continuing to grow at a fast pace, and the addition of Ellen and this team of practitioners is part of our strategic focus on expanding our capabilities to meet the needs of those clients," added John Rattigan, managing partner of DLA Piper's Boston office.
Scordino and Krumplitsch both join from Cooley LLP. Scordino received her J.D. from Fordham University School of Law and her B.S. in chemistry from Trinity College. Krumplitsch received her J.D. from Northeastern University School of Law, her M.S. in immunology and infectious disease from Harvard University School of Public Health and her B.A. from the University of California, Los Angeles. Isaacson joins from Impax Laboratories and was previously a partner at Goodwin Procter LLP. She received her J.D. from Vanderbilt University School of Law, her M.S. in pharmacological and physiological sciences from the University of Chicago and her A.B. in biological sciences from Mount Holyoke College.
